Progesterone for preterm birth prevention: an evolving intervention

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 3, 2009, Pages 219-224

  Tita, Alan Thevenet N ^a   Rouse, Dwight J ^a  

^a Center for Women's Reproductive Health   (United States)

Author keywords

preterm birth; prevention; progesterone

Indexed keywords

HYDROXYPROGESTERONE; PLACEBO; PROGESTERONE;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; EVENING DOSAGE; FATIGUE; GESTATIONAL AGE; HEADACHE; HUMAN; IMMINENT ABORTION; INCIDENCE; INJECTION SITE REACTION; META ANALYSIS; MULTIPLE PREGNANCY; NEWBORN DEATH; OUTCOME ASSESSMENT; PERINATAL DEATH; PERINATAL MORBIDITY; PERINATAL MORTALITY; PREMATURE LABOR; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; RESPIRATORY DISTRESS SYNDROME; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN BRUISING; SOMNOLENCE; SWELLING; SYSTEMATIC REVIEW; TREATMENT DURATION; UTERINE CERVIX;

FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; PROGESTINS; RISK FACTORS;

EID: 60849092545     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.12.035     Document Type: Review

References (23)

1. Goldenberg R.L., Culhane J.F., Iams J.D., and Romero R. Epidemiology and causes of preterm birth. Lancet 371 (2008) 75-84
2. Moster D., Lie R.T., and Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med 359 (2008) 262-273
3. Martin J.A., Hamilton B.E., Sutton P.D., et al. Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System births: final data for 2005. Natl Vital Stat Rep 56 (2007) 1-103
4. American College of Obstetricians and Gynecologist. Use of progesterone to reduce preterm birth: ACOG committee opinion No. 2919. Obstet Gynecol 102 (2003) 1115-1116
5. Farine D., Mundle W.R., and Dodd J. The use of progesterone for prevention of preterm birth. J Obstet Gynaecol Can 30 (2008) 67-71
6. Borna S., and Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labor: a randomized controlled trial. Aust N Z J Obstet Gynaecol 48 (2008) 58-63
7. Rouse D.J., Caritis S.N., Peaceman A., et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 357 (2007) 454-461
8. Fonseca E.B., Celik E., Parra M., Singh M., and Nicolaides K.H. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357 (2007) 462-469
9. O'Brien J.M., Adair C.D., Lewis D.F., et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 30 (2007) 687-696
10. DeFranco E.A., O'Brien J.M., Adair C.D., et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 30 (2007) 697-705
11. Facchinetti F., Paganelli S., Comitini G., Dante G., and Volpe A. Cervical length changes during preterm cervical ripening: effects of a 17-a-hydrosyprogesterone caproate. Am J Obstet Gynecol 196 (2007) 453.e1-453.e4
12. Meis P.J., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348 (2003) 2379-2385
13. da Fonseca E.B., Bittar R.E., Carvalho M.H.B., and Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 188 (2003) 419-424
14. Sanchez-Ramos L., Kaunitz A.M., and Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Am J Obstet Gynecol 105 (2005) 273-279
15. Dodd J.M., Crowther C.A., Cincotta R., Flenady V., and Robinson J.S. Progesterone supplementation for preventing preterm birth: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 84 (2005) 526-533
16. Dodd J.M., Flenady V., Cincotta R., and Crowther C.A. Prenatal administration of progesterone for preventing preterm birth [review]. Cochrane Database Syst Rev 2 (2006) CD004947
17. Mackenzie R., Walker M., Armson A., and Hannah M.E. Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol 194 (2006) 1234-1242
18. Coomarasamy A., Thangaratinam S., Gee H., and Khan K.S. Progesterone for the prevention of preterm birth: a critical evaluation of evidence. Eur J Obstet Gynecol Reprod Biol 129 (2006) 111-118
19. Dodd J.M., Flenady V.J., Cincotta R., and Crowther C.A. Progesterone for the prevention of preterm birth. Obstet Gynecol 112 (2008) 127-134
20. American College of Obstetricians and Gynecologist. Use of progesterone to reduce preterm birth: ACOG committee opinion No. 419. Obstet Gynecol 112 (2008) 963
21. Miles R.A., Paulson R.J., Lobo R.A., Press M.F., Dahmoush L., and Sauer M.V. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 62 (1994) 485-490
22. Cicinelli E., de Ziegler D., Bulletti C., Matteo M.G., Schonauer L.M., and Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 95 (2000) 403-406
23. Northen A.T., Norman G.S., Anderson K., et al. National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network: follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 110 (2007) 865-872